In HER–2–overexpressing breast cancer and triple–negative breast cancer (TNBC) patients, the rate of pCR can reach 40–50% with neoadjuvant treatment, and the long–term survival of patients achieving pCR is significantly better. This evidence concerns the gene ERBB2 and breast cancer.